Garfunkel Wild's collective experience in life sciences, technology, health care, and business, results in a cross-disciplinary team that is well-suited to collaborate with our biotechnology, life science, and medical device clients and help them capitalize on the promise and potential of technological innovation across the health care industry.
Our clients include:
Our attorneys draw from their degrees in scientific and technical fields and their practical experience in life sciences industries to function as part of our clients’ strategic teams, to anticipate needs, and to provide efficient and effective advice that addresses the unique concerns of our clients.
Our firm offers a full range of services to support our clients’ strategic needs and objectives in all stages of the business life cycle, including assistance with:
- Major universities conducting world-class scientific research
- Established pharmaceutical, bio-pharma, and medical device companies developing and commercializing products
- Emerging growth companies in-licensing technologies or collaborating with multi-national partners
- Inventors, entrepreneurs, spinouts, and start-ups devising plans to disrupt the industry status quo
Our attorneys draw from their degrees in scientific and technical fields and their practical experience in life sciences industries to function as part of our clients’ strategic teams, to anticipate needs, and to provide efficient and effective advice that addresses the unique concerns of our clients.
Our firm offers a full range of services to support our clients’ strategic needs and objectives in all stages of the business life cycle, including assistance with:
- Formation and corporate governance
- Seed, venture, and private equity financing
- Real estate matters
- Employment matters
- Equity plans and compensation
- Intellectual property matters
- Strategic partnerships, collaborations, and licensing arrangements
- Clinical research arrangements
- Commercialization, manufacturing, and distribution arrangements
- Privacy and data protection
- Regulatory matters including fraud and abuse issues and Sunshine Act reporting
- Litigation and alternative dispute resolution
- Mergers and acquisitions
- Other critical matters clients face in the biotechnology, pharmaceutical, and medical device industries.
Insights
March 1, 2024
OIG Issues New Resource for Single Audits
For More Information
Merton G. Gollaher
Partner